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The naphthoquinone shikonin, a major component of the root of Lithospermum erythrorhizon, now is studied as an anti-
inflammatory agent in the treatment of ulcerative colitis (UC). Acute UC was induced in Balb/Cmice by oral administration of 5%
dextran sodium sulfate (DSS). The disease activity index was evaluated, and a histologic study was carried out. Orally administered
shikonin reduces induced UC in a dose-dependent manner, preventing the shortening of the colorectum and decreasing weight
loss by 5% while improving the appearance of feces and preventing bloody stools. The disease activity index score was much lower
in shikonin-treated mice than in the colitic group, as well as the myeloperoxidase activity. The expression of cyclooxygenase-2
was reduced by 75%, activation of NF-κB was reduced by 44%, and that of pSTAT-3 by 47%, as well as TNF-α, IL-1β, and IL-6
production. Similar results were obtained in primary macrophages culture. This is the first report of shikonin’s ability to attenuate
acute UC induced by DSS. Shikonin acts by blocking the activation of two major targets: NF-κB and STAT-3, and thus constitutes
a promising potential therapeutic agent for the management of the inflammatory bowel disease.
1. Introduction
UC is a chronic intestinal disorder with recurrent episodes
of remission and relapse [1]. Diﬀuse mucosal inflammation
of the rectum and often a variable length of the colon
characterize the disease. The European Crohn’s and Colitis
Organization (ECCO) diﬀerentiates UC into one of three
types according to the disease distribution: proctitis (only the
rectum is aﬀected), left-sided or distal colitis, and extensive
colitis (parts of the colon next to the splenic flexure are also
involved) [2]. Patients with UC commonly report symptoms
such as diarrhea, rectal bleeding, and fatigue, which adversely
impact daily functioning [3]. The incidence of UC diﬀers
across countries (0.5 to 24.5 per 100000) and increases being
reported in some countries with previously lower incidences,
such as those in Eastern Europe and Asia [4]. Although
the exact pathogenesis of this disease is poorly understood,
infections, environmental factors, complex genetic disorders,
and a deregulation of the immune response have been
proposed as the main causes of the disease [5–7]. The
presence of UC appears to increase the risk of extraintestinal
diseases (e.g., iritis/uveitis, primary sclerosing cholangitis,
or ankylosing spondylitis) [8], other chronic inflammatory
diseases (e.g., arthritis, asthma, or multiple sclerosis) [9], or
colorectal cancer [10].
Cytokines are key signals in the intestinal immune
system and are known to participate in the disruption
of the so-called normal state of controlled inflammation
(physiological inflammation of the gut). In inflammatory
bowel disease, the innate immune response plays a critical
role. Activated dendritic cells and macrophages secrete
several cytokines that actively regulate the inflammatory
response in UC [11]. Diﬀerent studies have reported that
proinflammatory cytokines such as tumor necrosis factor
(TNF)-α, interleukin (IL)-1β, and IL-6 are increased in the
colonic mucosa of UC patients [12]. TNF-α expression in
human macrophages has been described in the colonic tissue
and in macrophages of patients with Crohn’s disease and
UC. Moreover, serum levels of TNF-α correlate with clinical
and laboratory indices of intestinal disease activity. IL-1β
is a proinflammatory cytokine produced predominantly by
stimulated macrophages and monocytes and its enhanced
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production has been detected at both the mRNA and protein
levels in patients and in DSS-induced colitis models. In
addition, increased productions of inducible nitric oxide
synthase and cyclooxygenase-2 have also been found in
inflammatory bowel disease, as well as in models of intestinal
inflammation [13]. The transcription factor NF-κB is one of
the major regulatory components in the complex scenario
of inflammatory bowel disease. Obviously the expression
and activation of NF-κB is strongly induced in the inflamed
gut of inflammatory bowel disease patients. NF-κB is not
just expressed but is also in a state of activation in mucosal
macrophages and epithelial cells in inflammatory bowel
disease patients. The amount of activated NF-κB correlates
with the severity of intestinal inflammation. The increased
NF-κB expression in macrophages is accompanied by an
increased capacity of these cells to produce and secrete
TNF-α, IL-1β, and IL-6, but predominantly NF-κB-induced
cytokines are responsible for further stimulation, activa-
tion, and diﬀerentiation of lamina propria immune cells,
resulting in the perpetuation of mucosal inflammation [14].
In fact, many of the immunosuppressive drugs currently
used in inflammatory bowel disease treatment, such as
corticosteroids, sulfasalazine, methotrexate, and anti-TNF-
α antibodies, are known to mediate their anti-inflammatory
eﬀects, at least partly, via inhibition of this transcription
factor.
The goal of treatment for inflammatory bowel disease
is to eliminate inflammation in order to provide symptom
relief and mucosal healing. Aminosalicylates remain the
cornerstone of therapy for patients with active, mild-to-
moderate UC. However, its role in Crohn’s disease has been
more controversial. Corticosteroids also remain popular
medications for inducing remission in both UC and Crohn’s
disease. However, they cannot eﬀectively maintain remission,
and their significant adverse eﬀects limit their long-term use.
When inflammatory bowel disease patients do not respond
to first-line therapy, the immunosuppressive therapy with
azathioprine and 6-mercaptopurine is often used. However,
only 40% of patients receiving azathioprine remain in
remission after one year. Thus, additional safe and eﬀective
treatment options are needed for these patients [15].
Despite the advancements that have been made in
treating patients with anti-TNF therapy and other drugs, a
large number of patients still need surgery.
Because of a lack of safety and eﬃcacy of standard
therapies, the use of complementary therapies such as
natural products and dietary components is fast becoming
an attractive approach for the treatment of inflammatory
bowel disease. Several plant constituents have been reported
to be useful in the management of inflammatory bowel
disease and other chronic inflammatory processes [16].
Among these, polyphenols such as rutin [15], thearubigin
[17], or curcumin [18, 19] and other polyphenols exhibit
intestinal anti-inflammatory activity [20]. The activity of
these natural molecules can be associated with broad
inflammatory parameters including morphological param-
eters, myeloperoxidase activity, glutathione levels, cytokine
production (TNF-α, IL-1β, and IL-6), p38-MAPK, and NF-
κB activation.
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Figure 1: Chemical structure of shikonin.
Traditional Chinese medicine continues to provide front-
line pharmacotherapy for many millions of people world-
wide. One example is the root of Lithospermum erythrorhizon
Sieb. et Zucc. (Boraginaceae) applied to treat macular
eruptions, measles, sore throats, carbuncles, and burns [21].
A major component of this plant is shikonin (Figure 1),
a natural naphthoquinone derivative. This compound has
been reported to possess diﬀerent medicinal properties
such as antibacterial, wound healing, anti-inflammatory,
antithrombotic, and antitumor eﬀects [22]. In a previous
work, our group has demonstrated that the dichloromethane
extract of L. erythrorhizon inhibited acute ear and paw edema
induced in mice via topical application of TPA and plantar
subcutaneous injection of carrageenan, respectively [23]. We
also demonstrated that the main compound present in this
extract, shikonin, reduces 12-O-tetradecanoylphorbol 13-
acetate-induced acute ear inflammation in vivo by inhibiting
NF-κB translocation to the nucleus as well as by interfering
with IκBα degradation. Both of these eﬀects were also
observed in vitro in the murine RAW 264.7 macrophage cell
line [24]. In the present study, we examined the eﬀects of
shikonin on changes in clinical symptoms and expression of
various proinflammatory mediators in DSS-induced colitis
mice. This experimental model is widely used to study the
pathogenic mechanisms underlying inflammatory bowel dis-
ease as well as to evaluate new intestinal anti-inflammatory
agents. Because this murine model resembles human UC,
it allows us to evaluate whether shikonin could serve as a
new therapeutic tool for treating patients suﬀering from this
disease.
2. Materials and Methods
2.1. Chemicals. Shikonin was purchased from TCI Europe
(Zwijndrecht, Antwerp, Belgium). All chemical and bio-
chemical reagents were purchased from Fluka Chemika-
Biochemika (Buchs, Switzerland), Baker (Deventer, Hol-
land), Panreac (Barcelona, Spain), and Sigma-Aldrich (St.
Louis, MO, USA).
2.2. Animals. Female Balb/C mice weighing 18–20 g (Harlan
Interfauna Ibe´rica, Barcelona, Spain) were used for in vivo
experiments. All animals were fed a standard diet ad libitum
and housed under a 12 h light/dark cycle at 22◦C and 60%
humidity. Housing conditions and all in vivo experiments
were approved by the Institutional Ethics Committee of the
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Table 1: Scoring system to calculate the disease activity index.
Scoring of disease activity index (DAI∗∗)
Score Weight loss Stool consistency Visible blood in feces
0 None
Normal None
1 1–5%
2 6–10%
Loose Slight bleeding
3 11–20%
4 >20% Diarrhea Gross bleeding
∗∗
The DAI value is calculated as the sum of scores of weight loss, stool
consistency, and blood in feces.
University of Valencia, Spain, according to the normative of
October 2005 (RD1201/2005).
2.3. Induction of Acute UC and Treatment with Shikonin.
Acute colitis was induced by oral administration of 5%
DSS (molecular weight 36–50 kD; MP Biomedicals LLC,
Solon, OH, USA) (w/v) in fresh tap water ad libitum for
seven days (6–10 mice per group). Three other groups
of animals which also received 5% DSS in drinking
water were treated orally with shikonin twice during the
experiment (on day 1 and on day 5) at diﬀerent doses
(6.25, 12.5, and 25mg kg−1). Shikonin was dissolved in
water : ethanol : Tween 80 (10 : 1 : 1) and administered orally
with the aid of a gavage. A fifth group received only fresh tap
water (Figure 10). Water consumption was controlled for all
groups, and no major diﬀerences were detected. The disease
activity index was determined according to the parameters
outlined in Table 1 [25]. On termination of the experiment
on day eight, mice were killed by cervical dislocation, and
colonic tissues were dissected for further analysis. This
same protocol was carried out three times in independent
experiments.
2.4. Histology. Small (approximately 1 cm) sections of
excised colonic tissue were fixed in 10% paraformaldehyde
in phosphate-buﬀered saline (PBS, pH 7.4) and embedded
in paraﬃn. Sections (4 μm) were cut and stained with
haematoxylin and eosin. Histologic assessment of colonic
mucosa was carried out in a blinded fashion by a pathologist
as described previously (Table 2) [26].
2.5. Immunofluorescence Staining. The frozen sections of the
distal colon were fixed in in freshly prepared 4% parafor-
maldehyde in PBS buﬀer (pH 7.2) and stained to detect
lymphocyte and macrophage infiltration by immunofluo-
rescence using fluorescein isothiocyanate-(FITC-)conjugated
rat anti-mouse CD4+monoclonal antibody (Miltenyi Biotec,
Gladbach, Germany) or allophycocyanin-(APC-)conjugated
rat anti-mouse CD11b+ monoclonal antibody (Miltenyi
Biotec), respectively. The sections were mounted with
Fluoroshield mounting medium with 4′,6′-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich). The numbers of
CD4+ and CD11b+-positive areas were measured on five
randomly chosen visual fields at 200×magnification.
2.6. Myeloperoxidase Activity Assay. Colon samples from
mid to distal colon were rinsed with cold PBS, blotted
dry, and immediately frozen with liquid nitrogen. The
samples were stored at−80◦C until use. For myeloperoxidase
activity determination, samples were ground to powder
in a mortar. Myeloperoxidase activity was determined as
described by Suzuki et al. [27]. Briefly, about 40mg of tissue
was weighed for each sample and homogenized in 80mM
monopotassium phosphate/disodium phosphate buﬀer (pH
5.4) containing 0.5% hexadecyltrimethylammonium bro-
mide. After centrifugation, 100 μL of PBS, 85 μL of 22mM
monopotassium phosphate/disodium phosphate buﬀer, and
15 μL of hydrogen peroxide 0.017% were added to 30 μL
of the supernatant. The enzymatic reaction begins when
adding 20 μL of tetramethylbenzidine hydrochloride. After
3min at 37◦C the reaction is stopped. Absorbance is read at
630 nm. Myeloperoxidase activity is expressed as the amount
of enzyme required to convert 1 μmol of hydrogen peroxide
to water in 1min, expressed per gram of wet weight of tissue.
2.7. Preparation of Cytosolic and Nuclear Fractions from
Colon. Protein extraction from the intestine was performed
as described previously by Sugimoto et al. [18]. In brief,
tissues were homogenized for 1min with a Polytron PT-2000
(Kinematica AG, Lucerne, Switzerland) tissue homogenizer
in 1.5mL of ice-cold buﬀer A (10mM 4-(2-hydroxyethyl)-1-
piperazineethane sulfonic acid (HEPES) pH 7.9, 10mMKCl,
1.5mM MgCl2, 0.5mM dithiothreitol, 0.1mM ethylene-
diaminetetraacetic acid (EDTA), 0.5mM phenylmethyl
sulphonyl fluoride, 1 μgmL−1 aprotinin, 1 μgmL−1 leu-
peptin, and μgmL−1 pepstatin A). Igepal CA-630 was added
to a final concentration of 0.5%. The homogenates were
chilled on ice with gentle shaking for 45min. The membrane
fraction was precipitated by means of centrifugation at
106×g for 10min at 4◦C. The supernatant containing the
cytosolic fraction was stored at −80◦C until use. The pellet
was resuspended with vortex in 500 μL of buﬀer B (20mM
HEPES pH 7.8, 400mM NaCl, 1.5mM MgCl2, 0.2mM
EDTA, 25% glycerol, 0.5mM phenylmethylsulphonyl fluo-
ride, 0.5mM dithiothreitol, 1 μgmL−1 aprotinin, 1 μgmL−1
leupeptin, and 1 μgmL−1 pepstatin A) and chilled during
30 min on ice with gentle shaking. After centrifugation at
20800×g for 15min at 4◦C, the supernatant containing the
nuclear fraction was removed and stored at −80◦C until
use. Cell lysates (30 μg of protein) were boiled in sodium
docecyl sulphate sample buﬀer for 5min before undergoing
electrophoresis.
2.8. Western Blot Analysis for Cyclooxygenase-2, NF-κB
p65, and Phosphorylated Signal Transducer and Activator of
Transcription (pSTAT)3. After extraction, the presence of
proteins in the supernatants was determined by means of
the Bradford method with bovine serum albumin as the
standard. Equal amounts of protein (30 μg) were then loaded
onto 10% sodium dodecyl sulphate polyacrylamide elec-
trophoresis gel and transferred onto polyvinylidene diflu-
oride membranes at 125mA for 90min. The membranes
were then blocked in PBS-Tween 20 containing 3%w/v
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Table 2: Histologic scoring system for DSS-induced colitis.
Scoring of severity of histological damage
Feature Score Description
Severity of inflammation
0 None
1 Mild
2 Moderate
3 Severe
Extent of inflammation
0 None
1 Mucosa
2 Mucosa and submucosa
3 Transmural
Crypt damage
0 None
1 1/3 damaged
2 2/3 damaged
3 Crypts lost, surface epithelium present
4 Crypts lost and surface epithelium lost
∗∗
Scores were calculated by adding the score for the three parameters, giving a maximum score of 10.
defatted milk. For cyclooxygenase-2, the membranes were
incubated with anticyclooxygenase-2 polyclonal antibody
(1 : 1000), obtained from Cayman (Ann Arbor, MI, USA).
For p65, the membranes were incubated with anti-p65
polyclonal antibody (1 : 500 dilution, SC-7151); for pSTAT-
3, the membranes were incubated with anti-pSTAT-3 (SC-
8019, 1 : 500 dilution); and for poly(ADP-ribose) polymerase
(PARP), the membranes were incubated with anti-PARP
polyclonal antibody (SC-1562, 1 : 400 dilution), all of them
purchased from Santa Cruz Biotechnologies (Santa Cruz,
CA, USA). Finally, for β-actin, the membranes were incu-
bated with anti-β-actin polyclonal antibody (1 : 10000 dilu-
tion), obtained from Sigma-Aldrich. The blots were washed
and incubated with peroxidase-conjugate anti-rabbit, anti-
mouse, or anti-goat immunoglobulin G (1 : 12000 dilution;
Cayman). The immunoreactive bands were visualized with
the aid of an enhanced chemilumeniscence system (Millipore
Corporation, Billerica, MA, USA).
2.9. Culture of Colon Organ Cells. After the in vivo protocol,
the colon of three mice was removed, opened longitudinally
and washed in PBS, as previously described by Siegmund
et al. [28]. The colon was then further cut into 1 cm
segments and cultured in complete Roswell Park Memorial
Institute (RPMI)-1640 medium supplemented with 10%
fetal calf serum, penicillin (100UmL−1), and streptomycin
(100UmL−1) in a 24-well plate. After 24 h, supernatant was
collected and stored at −80◦C until use and each intestinal
segment was weighed.
2.10. Mouse Peritoneal Macrophages Isolation. Balb/C mice
from a separate set of experiments were given a 1.5mL
intraperitoneal injection of 3% thioglycollate in water. Four
days later, mouse peritoneal macrophages were collected by
peritoneal lavage with PBS, pelleted, and washed in PBS.
Cells were plated at a density of 1 × 106 cellsmL−1 with Dul-
becco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal calf serum, penicillin (100UmL−1), and
streptomycin (100UmL−1). Cells were given 2 h to adhere,
medium was changed, and adherent cells were used for
cytokine and nitrite assays.
2.11. RNA Extraction and Reverse Transcription-Polymerase
Chain Reaction (RT-PCR). Mouse peritoneal macrophages
(106 cells per well) were pretreated with shikonin for 1 h
and then stimulated with lipopolysaccharide (1 μgmL−1)
for 3 h. Cells were collected, and total RNA was extracted
with the aid of RNeasy mini spin (50) columns (Qiagen,
Hilden, Germany), in accordance with the manufacturer’s
instructions. The concentration of the extracted RNA was
calculated by measuring the optical density at 260 nm. The
ratio of the optical density at 260 nm to that at 280 nm
was always higher than 1.8. Aliquots of 1 μg of RNA were
transformed to first strand complementary deoxyribonu-
cleic acid (cDNA) with AﬃnityScript Multiple Temperature
Reverse Transcriptase (Agilent Technologies, Santa Clara,
CA, USA). Then, 1 μL of the resulting cDNA was mixed
with 0.75 μM primers (Invitrogen, Langley, OK) of IL-6
(sense: 5′-ATGCTGGTGACAACCACGGCC-3′; antisense:
5′-GGCATAACGCACTAGGTTTGCCGA-3′), IL-1β (sense:
5′-GCTGGAGAGTGTGGATCCCAAGCA-3′; antisense: 5′-
AGCGACCTGTCTTGGCCGAGG-3′), TNF-α (sense: 5′-
AGCCCACGTCGTAGCAAACCAC-3′; antisense: 5′-TAG-
ACCTGCCCGGACTCCGC-3′). β-Actin primers were pur-
chased from R&D Systems (Minneapolis, MN, USA). The
thermocycler conditions were 94◦C for 1 min, with an
annealing temperature of 55◦C for 1min and an elongation
temperature of 72◦C for 1min for the first 30 cycles, followed
by an elongation temperature of 72◦C for 10min. After the
reaction was completed, the amplified product was removed
from the tubes and run on 1% agarose gel.
2.12. Measurement of Cytokines. The concentrations of var-
ious cytokines in the culture supernatants of the colons
Evidence-Based Complementary and Alternative Medicine 5
Non-colitic Colitic Colitic + Colitic + Colitic +
0
1
2
3
4
5
6
7
8
9
10
2512.5 6.25
∗
∗∗∗
∗∗∗
Shikonin (mg kg−1)
C
ol
or
ec
tu
m
 le
n
gt
h
±
SE
M
 (
cm
)
DSS
6.25 12.5 25Shikonin
(mg kg−1)
+ + ++−
−−
Figure 2: Eﬀect of shikonin on colon length. The noncolitic group received fresh tap water ad libitum, and the colitic group received fresh
tap water with 5% DSS added to the water during 7 days. Three other groups of mice received the same tap water with 5% DSS and were
treated with two doses of 6.25, 12.5, or 25mg kg−1 of shikonin on days 1 and 5 of the experiment. At the end of the experiment, all mice were
killed by cervical dislocation and large intestines were removed. After washing with ice-cold phosphate-buﬀered saline, they were placed on
filter papers and measured without the cecum. Statistical analysis was performed using one-way analysis of variance followed by Dunnett’s
t-test. ∗P < 0.05, ∗∗∗P < 0.001 versus colitic group. The results shown are representative of three independent experiments with 6 to 10 mice
per group.
and of mouse peritoneal macrophages were measured using
an enzyme-linked immunosorbent assay kit (eBioscience,
San Diego, CA, USA) according to the manufacturer’s
instructions.
2.13. Nitrite Determination by Griess Assay. Nitric oxide lev-
els were assessed by nitrite quantification as described else-
where [29]. Briefly, 100 μL of mouse peritoneal macrophages
culture medium was incubated for 15min with Griess
reagent (Sigma-Aldrich). Absorbance was read at 540 nm.
2.14. Software. Images for all western blot and PCR exper-
iments were acquired with the image analysis system LAS-
3000 mini (Fujifilm, Tokyo, Japan). Digital images were
processed and band density measurements were made with
the aid of a Multi Gauge V3.0 software package (Fujifilm).
2.15. Statistical Analysis. Statistical analysis was performed
by means of one-way analysis of variance (ANOVA) and
Dunnett’s t-test. The results are presented as the mean ±
SEM GraphPad Prism 4.0 software (GraphPad Software Inc.,
San Diego, CA, USA) was used for all calculations.
3. Results and Discussion
3.1. Eﬀects of Shikonin Treatment on Clinical Symptoms. We
assessed the systemic eﬀect of shikonin using the acute DSS-
induced UCmodel. For seven days mice received either fresh
tap water or 5%DSS dissolved in fresh tap water. Three other
groups received 5% DSS and were administered shikonin
(6.25, 12.5, or 25mg kg−1) orally both at the beginning of
the experiment and on day five (n = 6–10 for each group).
The DSS-induced murine UC model used in this study
is a well-established general prototype of intestinal tissue
damage that accurately resembles the histological aspects
of the tissue damage observed in patients suﬀering from
inflammatory bowel disease [30]. In this experimental
protocol of acute colitis, shikonin was found to exert an
anti-inflammatory eﬀect after only two administrations
(Figure 2) in a dose-dependent manner. In the case of the
colorectum length, colitic mice suﬀered a shortening of 43%
when compared to noncolitic mice. Shikonin significantly
prevented this shortening being only 30% at a dose of
12.5mg kg−1 (6.77±0.22 cm versus 9.61±0.20 cm in noncol-
itic mice, P < 0.05) and 11% at a dose of 25mg kg−1 (8.51±
0.19mm versus 9.61±0.20 cm in noncolitic mice, P < 0.001).
Moreover, shikonin-treated mice showed improvements in
body weight, appearance of feces and alleviation of bloody
stool. The disease activity index score, an indicator of the
severity of intestinal inflammation, was 8.79 ± 0.53 in the
colitic group. Shikonin treatment resulted in a significantly
lower disease activity index score, being 3.75 ± 0.25 in the
group treated with shikonin 12.5mg kg−1 and 1.90 ± 0.53
in the group treated with shikonin 25mg kg−1 (Figure 3).
Shikonin thus ameliorated all symptoms of DSS-induced
inflammation in mice (P < 0.0001).
Since the best macroscopic results were obtained with the
dose of 25mg kg−1 of shikonin, we continued the rest of the
experiments with the samples obtained from this group.
Histological analyses revealed that shikonin 25mg kg−1
treatment improved colonic architecture in comparison with
that of colitic mice; the treated group was assigned a tissue
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Figure 3: Eﬀect of shikonin on the disease activity index. Disease
activity index was evaluated for colitic groups (black bars) and
shikonin-treated colitic groups on termination of the experiment
according to the scoring on Table 1. ∗∗∗Significantly diﬀerent from
the colitic group (P < 0.001; one-way analysis of variance followed
by Dunnett’s t-test).
damage score of 1.67± 0.34 versus 8.47± 0.37 for the colitic
group (P < 0.001). Colitic mice exhibited marked cryptic
distortion, erosion of the lamina propria mucosae, inflam-
matory cell infiltration, and the disappearance of mucus
membrane cells (Figure 4(b)). Treatment with shikonin
actually restored the damaged colon, which displayed a
moderate inflammatory infiltrate (arrow). Restoration of
crypt architecture with goblet cell replenishment of mucin
was also observed (star) (Figure 4(c)).
By immunofluorescence, we observed a large number
of lymphocytes and macrophages in the colonic samples
from colitic mice, mainly located in the mucosa. Shikonin
treatment prevented this infiltration (Figure 5).
Consistent with these histologic and immunofluores-
cence findings, we can observe in Figure 4(e) an increase
in colonic myeloperoxidase activity in colitic animals. Oral
administration of 25mg kg−1 of shikonin is able to signifi-
cantly reduce in a 38% (P < 0.05) of this increase.
Taken together, our results indicate that shikonin can
markedly reduce inflammatory cell infiltration in the colon
of colitic mice.
3.2. Shikonin Limits Colonic Proinflammatory Cytokine
Expression. The recruitment of circulating leukocytes into
the colon leads to the release of proinflammatory mediators,
including proinflammatory cytokines such as IL-1β, IL-6,
IFN-γ, and TNF-α [31] and proinflammatory synthases such
as inducible nitric oxide synthase and cyclooxygenase-2 [32,
33]. To determine whether shikonin limits the production of
proinflammatory cytokines, therefore protecting the colonic
mucosa, we measured the levels of IL-6, TNF-α, IFN-γ, and
IL-1β in the supernatant of cultured colons of 5% DSS-
exposedmice given control diet or 25mg kg−1 of shikonin. As
Figure 6 shows, treatment with shikonin significantly reduces
the levels of these proinflammatory cytokines in about 50%
when determined in the whole colon. Since DSS-induced
UC in mice appears to be more severe in the distal colon,
we measured the production of cytokines in each area of
the colon and analyzed the eﬀect of shikonin per area.
As shown in this same Figure, DSS significantly increases
the production of all proinflammatory cytokines both in
mid and in distal colon. Shikonin tends to decrease the
production of all cytokines analyzed in both areas. In the mid
colon, treatment with shikonin results in a 61% reduction
of the production of IL-6, 29% reduction of TNF-α, 75%
reduction of IFN-γ, and 51% reduction of IL-1β, although
these inhibitions were statistically significant only for IFN-γ
and IL-1β. In the distal colon, as in the case of the mid colon,
the production of all measured cytokines was reduced, being
the inhibition of IL-6 (52%) and IFN-γ (74%) statistically
significant.
These data suggest that shikonin may lessen the dam-
aging eﬀects of DSS by suppressing the expression of
proinflammatory cytokines. These results agree with Dai
et al. (2009) [32], who used a model of collagen-induced
arthritis to show that the antiarthritic activity of shikonin
occurs through inhibition of Th1 cytokines.
3.3. Eﬀect of Shikonin on Nitric Oxide Production, Cytokine
Production, and Gene Expression in Mouse Peritoneal Macro-
phages. To help explain the amelioration in the curse of the
disease observed in colitic mice treated with shikonin, we
studied in vitro the eﬀect of this naphthoquinone on the
production of nitric oxide and proinflammatory cytokines in
lipopolysaccharide-stimulated peritoneal macrophages from
female Balb/C mice. As shown in Figure 7(a), shikonin
0.5 μM counteracts significantly the production of nitric
oxide (85%).
Moreover, the release of IL-6 (62%) and IL-1β (84%) is
also significantly reduced at 0.5 μM and at 1 μM shikonin
inhibits significantly the release of TNF-α (46%) (Figures
7(b)–7(d)).
To provide further insight into the mechanism under-
lying the anti-inflammatory activity demonstrated by
shikonin, mRNA expression levels in peritoneal macrophages
of these same proinflammatory cytokines were measured by
RT-PCR. As shown in Figure 8, mRNA levels for IL-6, TNF-
α, and IL-1β in lipopolysaccharide-stimulated macrophages
were significantly increased. Those increases were signif-
icantly attenuated in shikonin pretreated macrophages in
concentrations of 0.5 and 1 μM. At 0.5 μM shikonin sig-
nificantly inhibits the expression of IL-6 (37%, P < 0.05)
and IL-1β (32%, P < 0.01); at 1 μM shikonin significantly
inhibits the expression of IL-6 (85%, P < 0.01), TNF-α (20%,
P < 0.05), and IL-1β (87%, P < 0.01).
3.4. Shikonin Decreases Cyclooxygenase-2 Protein Expression
and Nuclear Translocation of NF-κB p65 and pSTAT-3. COX-
2 plays an important proinflammatory role in the pathogen-
esis of inflammatory bowel disease. We thus evaluated the
eﬀect of shikonin on colonic cyclooxygenase-2 expression in
DSS-induced UC. As expected, DSS administration to mice
for 7 days produced an increase in colonic cyclooxygenase-2
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Figure 4: Eﬀect of shikonin treatment on histological parameters in acute ulcerative colitis. Three representative colonic haematoxylin/eosin
sections: mice received either fresh tap water (a), fresh tap water with 5% DSS (b), or fresh tap water with DSS 5% and treatment with
shikonin 25mg kg−1 (c) as described in Section 2. Inflammatory infiltrate (arrow); replenishment of goblet cells with mucin (star). (d) The
severity of inflammation (white bars), extent of inflammation (dotted bars), and crypt damage (lined bars) were determined as described
in Table 2. The data presented are representative of three independent experiments with 6 to 10 mice per group. The boundary of the
box indicates the 25th and 75th percentiles; the line within the box marks the median. Whiskers indicate the 90th and 10th percentile.
∗∗Significantly diﬀerent from the total histological score of the colitic group, determined bymeans of a one-way analysis of variance followed
by Dunnett’s t-test (P < 0.01). (e) Mucosal myeloperoxidase levels were measured to evaluate the eﬀect of shikonin on the number of
neutrophils infiltrating the colon. ∗P < 0.05, ∗∗P < 0.01; significantly diﬀerent from the colitic group; #P < 0.05, ##P < 0.01; significantly
diﬀerent from the noncolitic group, determined by means of a one-way analysis of variance followed by Dunnett’s t-test (n = 6).
expression (Figure 9(a)) as detected by western blot analysis.
The anti-inflammatory eﬀect exerted by shikonin in the
intestine was associated with a significant (90%; P <
0.01) inhibition of colonic cyclooxygenase-2 expression
(Figure 9(a)) in comparison with colitic animals.
We also examined the eﬀect of shikonin on the activation
of NF-κB and pSTAT-3 in the colon homogenates. Transcrip-
tion factors of the NF-κB family play an essential role in the
regulation of genes involved in the immune and inflamma-
tory response. The promoter and enhancing regions of genes
coding inflammatory mediators have binding sites for NF-
κB [34]. In inflammatory bowel disease, NF-κB activation is
observed in inflamed intestinal mucosa, in which it induces
the expression of COX-2. Indeed, this activity has shown
to be higher in nuclear extracts of lamina propria biopsy
samples of patients with Crohn’s disease and with UC [35]
as well as in macrophages and epithelial cells of UC patients
[36], suggesting that targeting NF-κB activity in these cells
might be an attractive goal for therapeutic intervention
[14]. We verified that nuclear p65 levels were markedly
higher in mice that received DSS as compared to those that
only received normal drinking water (Figure 9(b)). Shikonin
partially prevented the translocation of p65 to the nucleus by
57% (P < 0.01) (Figure 9(b)) in comparison with the colitic
group. Blocking the NF-κB pathway could constitute an
interesting approach to break the vicious circle. Specifically,
the NF-κB p65 subunit seems to be an important regulator
in intestinal inflammation in inflammatory bowel disease; in
fact, treatment with antisense or decoy oligonucleotides that
inhibit p65 has been shown to ameliorate the macroscopic
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Figure 5: Immunofluorescence detection of CD4+ lymphocytes and CD11b+ cells. Shikonin treatment reduces the presence of CD4+
lymphocytes and macrophages in the colon tissue of mice. Colons were obtained from the colitic group and from the shikonin-(25mg kg−1)
treated group and were processed for immunofluorescence analysis using CD4+ FITC-conjugated monoclonal antibody and CD11b+ APC-
conjugated monoclonal antibody; representative results from four independent animals are shown. Arrows indicate the positive stained cells.
Original magnification, 200×.
signs of colitis as well as the nuclear accumulation and
DNA binding activity of p65 protein in several models of
intestinal inflammation [37–39]. The rectal administration
of these antisense oligonucleotides in a model of DSS-
induced UC was eﬀective when administered on day 0 or
2 [40, 41]; however, no eﬀect was seen when administered
on day 7. These results suggest that treatment with NF-κB
antisense oligonucleotides has an inhibitory eﬀect on DSS-
induced colitis when administered in the early phases of
inflammation. In a previous study using a model of acute ear
edema induced by topical 12-O-tetradecanoylphorbol 13-
acetate application and lipopolysaccharide-stimulated RAW
264.7 macrophages, we demonstrated that shikonin’s anti-
inflammatory activity occurs through its inhibitory eﬀect on
NF-κB activation, which can, in turn, be attributed to its
ability to prevent IκBα degradation [24]. Moreover, a recent
pharmacogenomics study showed that shikonin inhibits a
group of genes associated with the early stages of the
inflammatory response, including cytokine, chemotaxis, and
cell migration genes [42]. Lu et al. [43] recently suggested
as a possible biochemical mechanism the inhibition of the
proteasome, which consequently inhibits the degradation of
IκBα, as they demonstrated in lipopolysaccharide-stimulated
rat primary macrophages treated with shikonin 1 μM. In the
present study, we have demonstrated that shikonin is able
to inhibit the expression of COX-2 in colon homogenates
of treated mice, probably by preventing the nuclear translo-
cation of the p65 subunit, as was the case with 12-O-
tetradecanoylphorbol 13-acetate-induced ear edema [24].
Recent data indicate that STAT-3 is one of the crucial tar-
gets for the treatment of inflammatory bowel disease as the
development of colonic inflammation is strongly associated
with the induction of STAT-3 activity. Upon activation, this
transcription factor translocates to the nucleus [44]. Mudter
et al. [45] and Atreya and Neurath [46] found that STAT-3
and pSTAT-3 levels are significantly higher in ulcerative coli-
tis patients in comparison with controls. Its overactivation in
monocytes and epithelial cells results in the innate defense
system allowing bacteria to fester and eventually initiate
the disease [47]. Moreover, STAT-3 and pSTAT-3 levels
also correlate with the histologic profile of experimental
inflammation tissues [48, 49]; therefore STAT-3 seems to be a
potential therapeutic target for ulcerative colitis. In previous
work, Bai et al. [50] studied the blockade of STAT-3 by
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Figure 6: Expression of cytokines in the supernatant of colonic culture by ELISA. Colons were cultured for 24 h, supernatants were collected,
and cytokines were measured in duplicate with ELISA. Left panels represent the levels of cytokines measured in the whole colon (after
removing cecum and anus); right panels represent the levels of cytokines measured in the diﬀerent areas of the colon (proximal, mid, and
distal area). Results are expressed as the concentration of cytokine referred to wet weight (pg mL−1mg−1) ±SEM and are representative of
three independent experiments with 2 colons per group. Diﬀerences with the colitic group were determined by means of a one-way analysis
of variance followed by Dunnett’s t-test (∗P < 0.05, ∗∗P < 0.01; significantly diﬀerent from the colitic group; #P < 0.05, ##P < 0.01;
significantly diﬀerent from the noncolitic group).
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Figure 7: Eﬀect of shikonin on nitric oxide and overall cytokine production in peritoneal macrophages isolated from Balb/C mice. Mouse
peritoneal macrophages were isolated and cultured for 24 h. Supernatants were collected, and nitrites and cytokines were measured in
duplicate. The B (blank) group represents untreated and unstimulated macrophages, C (control) group represents those macrophages
stimulated with lipopolysaccharide (1 μgmL−1), and finally two other groups were treated for 1 h with diﬀerent doses of shikonin (0.5 and
1 μM) prior to stimulation with lipopolysaccharide. Results are representative of ten independent experiments. Diﬀerences were determined
by means of a one-way analysis of variance followed by Dunnett’s t-test (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 significantly diﬀerent from
the control group; ##P < 0.01, significantly diﬀerent from the blank group).
antisense oligonucleotides in trinitrobenzenesulphonic acid-
(TNBS-)inducedmurine colitis. As can be seen in our results,
in noncolitic animals, only weak immunoreactivity was
detected in the nucleus for pSTAT-3 (Figure 9(c)). Similar
results were observed in the group of colitic mice treated
with shikonin (55% reduction in comparison with colitic
mice, P < 0.01). This finding suggests that an important
beneficial eﬀect of shikonin in the treatment of inflammatory
bowel disease is its ability to reduce the activation of STAT-
3. However, more studies are needed to gain further insight
into this mechanism.
One aspect that has not been assessed in this work
and which may be involved in the protective mechanism
of shikonin in experimental ulcerative colitis is the eﬀect
the compound may have on the gastrointestinal microbiota,
especially since it is administered orally. The intestinal
lumen has a large number of microorganisms in perfect
symbiosis with the host. These interactions can be beneficial
or detrimental. The intestinal immune system must, on the
one hand, defend from the attack of pathogens and thus
prevent excessive entry of germs through the epithelium and,
on the other, recognize the resident intestinal microflora.
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Figure 8: Expression of proinflammatory genes in peritoneal macrophages isolated from Balb/C mice. Proinflammatory gene expression
levels weremeasured using RT-PCR, as described in Section 2. Representative photographs from ten independent experiments with each gene
are shown. β-Actin served as the internal control. The expression seen in the lipopolysaccharide-stimulated group (control) was standardized
as 100% expression. ∗P < 0.05, ∗∗P < 0.01; significantly diﬀerent from the control group; #P < 0.05, ##P < 0.01; significantly diﬀerent from
the blank (unstimulated) group, determined by means of a one-way analysis of variance followed by Dunnett’s t-test (n = 10).
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Figure 9: Eﬀects of shikonin on cyclooxygenase-2 expression and on nuclear translocation of p65 and phosphorylated signal transducer
and activator of transcription 3. The left panels show an example of western blot following probing with the corresponding antibody. The
histograms at the right represent the data derived from the western blots following densitometry analysis. Levels were normalized against
β-actin or PARP-1 antibody. ∗∗P < 0.01 significantly diﬀerent from the colitic group; #P < 0.05, ##P < 0.01 significantly diﬀerent from the
noncolitic group, determined by means of a one-way analysis of variance followed by Dunnett’s t-test (n = 6–10).
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Figure 10: Induction of acute ulcerative colitis and treatment protocol.
The breakdown of this balance leads to inflammatory bowel
disease. Therefore, an important challenge is to identify and
understand these interactions since many factors (diet, med-
ication, therapy with antibiotics, etc.) can modify them. For
example, a defect in the permeability of the intestinal mucosa
may lead to a loss of tolerance to normal enteric flora.
The defects in the intestinal epithelial barrier observed
in ulcerative colitis lead to an increase in the concentration
of anaerobic bacteria. This explains the fact that antibiotics
and probiotic agents are more eﬀective and better tolerated
than immunosuppressants. The inflammation induced by
chemical agents such as DSS produces a profound change in
the colonic microbial community (Abraham and Medzhitov,
2011) [51], decreasing the concentration of Bacteroidetes
and increasing the relative number of Proteobacteria, includ-
ing Enterobacteriaceae, so if the host is genetically sus-
ceptible, it will respond to such pathogenic flora. Enter-
obacteriaceae such as Klebsiella pneumoniae or Escherichia
coli have N-acetyltransferase activity, which activates certain
carcinogens. While shikonin is not antimicrobial against
these bacteria, it is able to inhibit the enzyme [52] and
therefore play a protective role.
4. Conclusion
Shikonin treatment is eﬀective in UC induced by DSS at a
dose of 25mg kg−1 (twice p.o.). Shikonin reduces proinflam-
matory cytokine production and inhibits cyclooxygenase-
2 and inducible nitric oxide synthase expression in mice
with established colitis. The eﬀects of shikonin in this
experimental model may be explained not only by an
inhibition of Th1 responses, but also by the blockade of
the activation of two major targets: NF-κB and STAT-3.
This is the first report of shikonin’s ability to attenuate the
acute inflammation induced by oral administration of DSS.
The combination of the known anti-N-acetyltransferase
activity and wound healing properties of shikonin together
with its anti-inflammatory properties make it a promising
therapeutic agent for the management of inflammatory
bowel disease.
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